Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

RIDGEFIELD, Conn., Oct. 11 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.  In the phase IIb/III LUX-Lung 1 study, afatinib tripled the secondary endpoint of progression free survival (PFS) but did not extend the primary endpoint of overall survival (OS) in late-stage patients with non-small cell lung cancer (NSCLC).(1)      

Afatinib is an investigational orally administered irreversible inhibitor of both the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) tyrosine kinases.  Afatinib is under development in several solid tumors including NSCLC, breast and head and neck cancer.

The LUX-Lung 1 trial compared afatinib to placebo in over 580 patients with advanced NSCLC who had received chemotherapy and a prior EGFR tyrosine kinase inhibitor (EGFR TKI; gefitinib or erlotinib);(1) results show:

  • Afatinib did not improve OS compared to placebo – 10.78 months vs. 11.96 months, respectively (HR = 1.08, 95% CI 0.86 to 1.35)(1)
  • As a secondary endpoint, afatinib extended PFS three-fold compared to placebo (3.3 months vs. 1.1 months) (HR = 0.38, 95% CI 0.31 to 0.48, p<0.0001).  The improvement in PFS was apparent across all patient subgroups and has been confirmed by independent review(1)
  • At 8 weeks, there was a significantly higher disease control rate (stable disease and tumor shrinkage) in those patients who took afatinib (58%) vs. those taking placebo (19%), which was also independently verified (p<0.0001)(1)
  • Improvement of the lung cancer-related symptoms of cough, dyspnea and pain was observed in the afatinib arm vs. placebo.  In addition, the time to deterioration of cough, individual dyspnea items an
    '/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Ill. and PALO ALTO, Calif. ... Cystic Fibrosis Research, Inc. (CFRI) today announced a partnership ... cystic fibrosis (CF) community through the CFChef Shares program. ... 15, 2014, as part of AbbVie,s CFChef program – ... to encourage patients to maintain a healthy diet by ...
(Date:8/1/2014)... 1, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Phase 3 study evaluating ISIS-SMN Rx in infants ... cause of infant mortality. Isis plans to dose the ... weeks, at which time Isis will earn an $18 ... The Phase 3 study, ENDEAR, is the first of ...
(Date:8/1/2014)... 1, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... update and reported financial results for the second ... "We have continued to see encouraging advancements in ... quarter-over-quarter increase in estimated total prescriptions and estimated ... said Jack Lief, Arena,s President and Chief Executive ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
... Stiefel, a GSK company, today announced the launch of the ... the United States. The launch will occur in the technical ... New Orleans. Indicated for the treatment of acne, Stiefel will ...   PanOxyl ® Acne Creamy Wash will be available in ...
... MEDfx Corporation today announced a Direct Project pilot that ... of the standards and protocols supported by the Direct ... in, and is a contributor to, the nationally-sponsored Direct ... Health IT.  The MEDfx Direct pilot will be demonstrated ...
Cached Medicine Technology:Stiefel Launches Most-Prescribed BPO Wash Formulations Over-the-Counter 2MEDfx to Harmonize the Direct Project With CONNECT 2MEDfx to Harmonize the Direct Project With CONNECT 3
(Date:8/1/2014)... Home Care Assistance of Cincinnati , ... to be recognized as a 2014 Best of Home Care ... care providers who rank in the top 50th percentile in ... interviews conducted by Home Care Pulse. , “The Best ... the best of the best!” says Home Care Pulse Founder ...
(Date:8/1/2014)... 01, 2014 Ticket Down is a reputable ... Lane Farms in Knoxville/Greenback, TN; Ingram Farms in Auburn/Opelika, AL; ... in Archer/Gainesville, FL. Luke Bryan is currently out on his ... and Cole Swindell. Bryan is responsible for one of the ... and this year, just because the summer is over doesn’t ...
(Date:8/1/2014)... of Bioengineering and Nanotechnology (IBN), Singapore General Hospital ... co-developed the first molecular test kit that can ... patients. This breakthrough was recently reported in ... , According to IBN Executive Director Professor ... molecular diagnostics and cancer research, we have developed ...
(Date:8/1/2014)... 2014 CapsCanada, a leading provider ... a new K-CAPS® (HPMC capsules) manufacturing facility in ... plans last year while experiencing growing global demand ... Manager, “KCAPS® are currently sold in more than ... “Compared to other HPMC capsules, K-CAPS® have exceptional ...
(Date:8/1/2014)... 01, 2014 A new study ... carbohydrates may contribute to the development of colorectal cancer ... disease. The study was authored by Alberto Martin of ... to cause intestinal cells to multiply and create tumors ... cancer. , “What’s interesting about this study,” said ...
Breaking Medicine News(10 mins):Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 3Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 4Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3Health News:Carbs May Contribute to Colon Cancer 2
... died during the first days of January and many ... tuberculosis//. ,This was disclosed by the ... Indigenous Peoples' Organization (Opittamp), Elton Rodrigues Paes, who has ... the necessary treatment to the peoples in the River ...
... this week we’re looking at efforts to fight malaria. One ... IRS//. Insecticides are applied to the interior walls of homes ... disease. With IRS, protection can be guaranteed for up ... who chairs a U.N. Committee on Science and Technology and ...
... Researchers at UT Southwestern Medical Center have found a new ... to turn on genes could lead to therapeutics// for conditions ... This gene-activating method provides researchers with a novel research tool ... ,In a paper appearing online at Nature ...
... Medical School researchers report that a single protein in brain ... to insulin// and leptin, and energy balance. Their research findings ... cells were reported in the February issue of the Journal ... early to say how this protein could be useful in ...
... Government has come down heavily on alternative therapists who ... are about one lakh therapists said to exist in ... tab on these professionals. On the other hand, completely ... Medical Council have strict rules and guidelines regarding their ...
... announced that it is teaming up with Weight Watchers for ... fight obesity in more than 75000 people in the Mountain ... are eligible to take up this 16-week course from Weight ... points to different foods. This program is free, but participants ...
Cached Medicine News:Health News:Malaria and TB Kills Indian Kids in Brazil 2Health News:IRS Helps Curb Malaria in the Tropics 2Health News:A Novel Technique Nudges Genes Into Activity 2Health News:A Novel Technique Nudges Genes Into Activity 3Health News:A Protein in Brain Cells Controls Obesity: Research 2Health News:A Protein in Brain Cells Controls Obesity: Research 3Health News:A Protein in Brain Cells Controls Obesity: Research 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: